We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aspirin Reduces Cancer Risk by Restricting cAMP Production

By Biotechdaily staff writers
Posted on 14 Jul 2003
Researchers have found that the anticancer properties of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are due to their inhibition of the enzyme cyclo-oxygenase-2 (COX-2), which results in lowered production of cyclic adenosine monophoshate (cAMP), an inhibitor of apoptosis.

One of the earliest molecular events in 80% of colon cancers is overexpression of COX-2, a rate-limiting enzyme of prostaglandin (PG) production. More...
Prior studies have shown that long-term use of NSAIDs inhibits COX-2 and is associated with a 40-50% reduction in the incidence of colon cancer. In a new study published July 1, 2003, in the online edition of the Proceedings of the National Academy of Sciences, investigators at the University of California, San Diego (USA; www.ucsd.edu), identified the specific site where NSAIDs have a regulatory effect on apoptosis.

The study found that increased COX-2 activity caused the major PGE2 receptors on epithelial cells, EP2 and EP4, to increase cAMP production, which promotes growth and inhibits apoptosis in some cell types. Furthermore, substances that stimulated cAMP synthesis such as PGE2, cholera toxin, and a membrane-permeant cAMP analog, protected normal and transformed intestinal epithelial cells from apoptosis. This protection was associated with cAMP-mediated, rapid induction of cellular inhibitor of apoptosis protein (c-IAP)-2.

The authors concluded, "These results help to explain the cancer chemoprotective effects of nonsteroidal anti-inflammatory drugs by defining a mechanism through which cAMP signaling can promote the development of colorectal and possibly other epithelial cancers by means of disruption of normal apoptotic processes.”



Related Links:
University of California, San Diego

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.